Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wu, 2015, Incidence of Dravet Syndrome in a US Population, Pediatrics, 136, e1310, 10.1542/peds.2015-1807
Depienne, 2009, Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients, J Med Genet, 46, 183, 10.1136/jmg.2008.062323
Zuberi, 2011, Genotype-phenotype associations in SCN1A-related epilepsies, Neurology, 76, 594, 10.1212/WNL.0b013e31820c309b
Genton, 2011, Dravet syndrome: the long-term outcome, Epilepsia, 52, 44, 10.1111/j.1528-1167.2011.03001.x
Wolff, 2006, Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings, Epilepsia, 47, 45, 10.1111/j.1528-1167.2006.00688.x
Wirrell, E.C., et al., Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatr Neurol, 2017. 68: p. 18–34 e3.
Akiyama, 2010, A long-term follow-up study of Dravet syndrome up to adulthood, Epilepsia, 51, 1043, 10.1111/j.1528-1167.2009.02466.x
Takayama, 2014, Long-term course of Dravet syndrome: a study from an epilepsy center in Japan, Epilepsia, 55, 528, 10.1111/epi.12532
Wirrell, 2019, Recent Advances in the Drug Treatment of Dravet Syndrome, CNS Drugs, 33, 867, 10.1007/s40263-019-00666-8
Cross, 2019, Dravet syndrome: Treatment options and management of prolonged seizures, Epilepsia, 60, S39
de Lange, 2019, Outcomes and comorbidities of SCN1A-related seizure disorders, Epilepsy Behav, 90, 252, 10.1016/j.yebeh.2018.09.041
Licheni, 2018, Sleep problems in Dravet syndrome: a modifiable comorbidity, Dev Med Child Neurol, 60, 192, 10.1111/dmcn.13601
Lagae, 2018, Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey, Dev Med Child Neurol, 60, 63, 10.1111/dmcn.13591
Villas, 2017, Dravet syndrome: Characteristics, comorbidities, and caregiver concerns, Epilepsy Behav, 74, 81, 10.1016/j.yebeh.2017.06.031
Olivieri, 2016, Cognitive-behavioral profiles in teenagers with Dravet syndrome, Brain Dev, 38, 554, 10.1016/j.braindev.2015.12.014
Connolly, 2016, Dravet Syndrome: Diagnosis and Long-Term Course, Can J Neurol Sci, 43, S3, 10.1017/cjn.2016.243
Knupp, 2017, Parental Perception of Comorbidities in Children With Dravet Syndrome, Pediatr Neurol, 76, 60, 10.1016/j.pediatrneurol.2017.06.008
Eschbach, 2017, Growth and endocrine function in children with Dravet syndrome, Seizure, 52, 117, 10.1016/j.seizure.2017.09.021
Berg, A.T., et al., Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox-Gastaut syndrome, ESES: A functional framework. Epilepsy Behav, 2020. 111: p. 107287.
Nabbout, 2019, Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures, Dev Med Child Neurol, 61, 1229, 10.1111/dmcn.14186
Shmuely, 2016, Mortality in Dravet syndrome: A review, Epilepsy Behav, 64, 69, 10.1016/j.yebeh.2016.09.007
Jansson, J.S., T. Hallböök, and C. Reilly, Intellectual functioning and behavior in Dravet syndrome: A systematic review. Epilepsy Behav, 2020. 108: p. 107079.
Brown, A., et al., Cognitive, behavioral, and social functioning in children and adults with Dravet syndrome. Epilepsy Behav, 2020. 112: p. 107319.
Verheyen, K., et al., Independent walking and cognitive development in preschool children with Dravet syndrome. Dev Med Child Neurol, 2020.
Ceulemans, 2011, Overall management of patients with Dravet syndrome, Dev Med Child Neurol, 53, 19, 10.1111/j.1469-8749.2011.03968.x
Ishii, 2017, Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome, Epilepsia, 58, 282, 10.1111/epi.13639
Riva, D., et al., Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes. Am J Med Genet A, 2009. 149a(10): p. 2339–45.
Rilstone, 2012, Dravet syndrome: seizure control and gait in adults with different SCN1A mutations, Epilepsia, 53, 1421, 10.1111/j.1528-1167.2012.03583.x
Rodda, 2012, Progressive gait deterioration in adolescents with Dravet syndrome, Arch Neurol, 69, 873, 10.1001/archneurol.2011.3275
Black, 2016, Crouch Gait in Dravet Syndrome, Pediatr Neurol Briefs, 30, 42, 10.15844/pedneurbriefs-30-11-2
Claes, 2001, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy, Am J Hum Genet, 68, 1327, 10.1086/320609
Scheffer, 2019, SCN1A-related phenotypes: Epilepsy and beyond, Epilepsia, 60, S17
Catterall, 2018, Dravet Syndrome: A Sodium Channel Interneuronopathy, Curr Opin Physiol, 2, 42, 10.1016/j.cophys.2017.12.007
Berecki, 2019, SCN1A gain of function in early infantile encephalopathy, Ann Neurol, 85, 514, 10.1002/ana.25438
Loscher, 2020, Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options, Pharmacol Rev, 72, 606, 10.1124/pr.120.019539
Han, Z., et al., Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med, 2020. 12(558).
Lim, 2020, Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression, Nat Commun, 11, 3501, 10.1038/s41467-020-17093-9
Scharner, 2021, Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics, Mol Ther, 29, 540, 10.1016/j.ymthe.2020.12.022
Carvill, 2018, Aberrant Inclusion of a Poison Exon Causes Dravet Syndrome and Related SCN1A-Associated Genetic Epilepsies, Am J Hum Genet, 103, 1022, 10.1016/j.ajhg.2018.10.023
Mistry, 2014, Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice, Neurobiol Dis, 65, 1, 10.1016/j.nbd.2014.01.006
Liau, G., et al., TANGO OLIGONUCLEOTIDES FOR THE TREATMENT OF DRAVET SYNDROME: SAFETY,BIODISTRIBUTION, AND PHARMACOLOGY IN THE NON-HUMAN PRIMATE. AES 2019 Annual Meeting Abstract Database. AESnet.org., 2019. Abstr. 2.195.
Laux, L., et al., SAFETY AND PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDE STK-001 IN CHILDRENAND ADOLESCENTS WITH DRAVET SYNDROME: SINGLE ASCENDING DOSE DESIGN FOR THE OPEN-LABEL PHASE 1/2A MONARCH STUDY. AES 2020 Annual Meeting Abstract Database. AESnet.org., 2020. Abstr. 344.
Sadleir, 2017, Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype, Neurology, 89, 1035, 10.1212/WNL.0000000000004331
Meisler, 2019, SCN8A encephalopathy: Mechanisms and models, Epilepsia, 60, S86
Martin, 2007, The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy, Hum Mol Genet, 16, 2892, 10.1093/hmg/ddm248
Lenk, 2020, Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome, Ann Neurol, 87, 339, 10.1002/ana.25676
Ricobaraza, A., et al., High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy. Int J Mol Sci, 2020. 21(10).
Yu, 2006, Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy, Nat Neurosci, 9, 1142, 10.1038/nn1754
Liu, 2013, Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism, Ann Neurol, 74, 128, 10.1002/ana.23897
AN, Y., et al., A GABA-Selective AAV Vector-Based Approach to Up-Regulate Endogenous Scn1a Expression Reverses Key Phenotypes in a Mouse Model of Dravet Syndrome. Molecular Therapy, 2019. 27(4S1): p. Abstract 915.
Belle, A., et al., ETX101, A GABAERGIC INTERNEURON SELECTIVE AAV-MEDIATED GENE THERAPY FOR THETREATMENT OF SCN1A+ DRAVET SYNDROME: BIODISTRIBUTION AND SAFETY IN NON-HUMAN PRIMATES. AES 2020 Annual Meeting Abstract Database. AESnet.org., 2020. Abst. 391.
O'Malley, 2015, Sodium Channel beta Subunits: Emerging Targets in Channelopathies, Annu Rev Physiol, 77, 481, 10.1146/annurev-physiol-021014-071846
Bouza, A.A., et al., Sodium channel beta1 subunits participate in regulated intramembrane proteolysis-excitation coupling. JCI Insight, 2021 Feb 8;6(3):e141776. https://doi.org/10.1172/jci.insight.141776.
Niibori, 2020, Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome, Hum Gene Ther, 31, 339, 10.1089/hum.2019.225
Doudna, J.A. and E. Charpentier, Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014. 346(6213): p. 1258096.
Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829
Gasiunas, 2012, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria, Proc Natl Acad Sci U S A, 109, E2579, 10.1073/pnas.1208507109
Yamagata, T., et al., CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice. Neurobiol Dis, 2020. 141: p. 104954.
Colasante, 2020, dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice, Mol Ther, 28, 235, 10.1016/j.ymthe.2019.08.018
Ogiwara, I., et al., Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci, 2007. 27(22): p. 5903–14.
Wilson, 2009, Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency, Mol Genet Metab, 96, 151, 10.1016/j.ymgme.2008.12.016
Grimm, 2006, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways, Nature, 441, 537, 10.1038/nature04791
Bevan, 2011, Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol Ther, 19, 1971, 10.1038/mt.2011.157
Chand, 2021, Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy, J Hepatol, 74, 560, 10.1016/j.jhep.2020.11.001
Feldman, A.G., et al., Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. J Pediatr, 2020. 225: p. 252–258 e1.
Hinderer, 2018, Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN, Hum Gene Ther, 29, 285, 10.1089/hum.2018.015
Stevens, 2020, Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy, Ann Pharmacother, 54, 1001, 10.1177/1060028020914274
Waldrop, M.A., et al., Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Pediatrics, 2020. 146(3).
Darras, 2019, An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials, CNS Drugs, 33, 919, 10.1007/s40263-019-00656-w
Jason, 2004, Toxicology of antisense therapeutics, Toxicol Appl Pharmacol, 201, 66, 10.1016/j.taap.2004.04.017
Chan, 2006, Antisense oligonucleotides: from design to therapeutic application, Clin Exp Pharmacol Physiol, 33, 533, 10.1111/j.1440-1681.2006.04403.x
Connock, 2020, Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective, Expert Opin Biol Ther, 20, 823, 10.1080/14712598.2020.1772747
Dangouloff, 2021, Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments, Orphanet J Rare Dis, 16, 47, 10.1186/s13023-021-01695-7
Campbell, 2018, Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey, Epilepsy Behav, 80, 152, 10.1016/j.yebeh.2018.01.003
Jensen, 2017, The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research, Epilepsy Behav, 70, 104, 10.1016/j.yebeh.2017.02.003